Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials

Background Several cancer therapies have been associated with cardiovascular harm in early‐phase clinical trials. However, some cardiovascular harms do not manifest until later‐phase trials. To limit interdisease variability, we focused on breast cancer. Thus, we assessed the reporting of cardiovasc...

Descripció completa

Dades bibliogràfiques

Autors principals:	Arsalan Hamid, Markus S. Anker, John C. Ruckdeschel, Muhammad Shahzeb Khan, Arsal Tharwani, Adebamike A. Oshunbade, Rodney K. Kipchumba, Samuel C. Thigpen, Stefan D. Anker, Gregg C. Fonarow, Michael E. Hall, Javed Butler
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2022-08-01
Col·lecció:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Matèries:	cancer therapy cardio‐oncology cardiovascular disease pharmacotherapy safety
Accés en línia:	https://www.ahajournals.org/doi/10.1161/JAHA.121.025206
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!